Costs and Clinical Outcomes Associated with Use of Ranolazine for Treatment of Angina
Authors:
- Charles E. PhelpsCPCharles E. Phelps
- Erin K. BuysmanEBErin K. Buysman
- Gabriel Gomez ReyGRGabriel Gomez Rey
- 1 June 2012
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 34 (6) , 1395-1407.e4
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Economic Impact of Angina After an Acute Coronary SyndromeCirculation: Cardiovascular Quality and Outcomes, 2009
- Effect of PCI on Quality of Life in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2008
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJACC, 2004
- Estimating log models: to transform or not to transform?Journal of Health Economics, 2001
- The natural history of prevalent ischaemic heart disease in middle-aged menEuropean Heart Journal, 2000
- Modeling risk using generalized linear modelsJournal of Health Economics, 1999
- Natural history of myocardial infarction and angina pectoris in a general population sample of middle‐aged men: a 16‐year follow‐up of the Primary Prevention Study, Göteborg, SwedenJournal of Internal Medicine, 1998
- The logged dependent variable, heteroscedasticity, and the retransformation problemJournal of Health Economics, 1998
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987